Home · Health · Sep 25 archive
Study Shows Women Fare Better in Rare Skin Cancer
Confirmed
In Short: In related cancer news, the FDA has granted priority review to T-DXd for high-risk HER2-positive early breast cancer with residual disease, following a trial that showed markedly better recurrence-free survival compared to T-DM1.
A study published in Medscape revealed that women with extramammary Paget disease (EMPD) exhibit a lower risk of cancer-specific and all-cause mortality compared to men, based on data from the Surveillance, Epidemiology, and End Results (SEER) program from 2004 to 2021.
The research was supported in part by the Biostatistics Shared Resource of the Winship Cancer Institute at Emory University, which is funded by the National Institutes of Health/National Cancer Institute.
This finding adds to the growing body of evidence suggesting that gender may play a significant role in the survival rates of certain cancers.
The study highlights the importance of considering gender differences in cancer outcomes and treatment strategies.
While the study provides valuable insights, it does not establish the underlying mechanisms responsible for the observed survival differences between men and women with EMPD.
Further research is needed to explore the biological and environmental factors that contribute to these disparities.
Additionally, the combination of Inluriyo and another therapy doubled the median progression-free survival in the phase 3 EMBER-3 trial, compared to Inluriyo alone, with a PFS of 11 months versus five and a half months.
Dr. Komal Jhaveri of Memorial Sloan Kettering Cancer Center, the principal investigator for the EMBER-3 and EMBER-4 trials, emphasized the urgent need for effective and safe treatment options for patients with disease progression on adjuvant or first-line therapy.
The EMBER-4 study, involving 8,000 patients, is assessing Inluriyo's potential in reducing recurrence in early-stage breast cancer after standard of care endocrine therapy.
These advancements in cancer treatment underscore the ongoing efforts to improve patient outcomes and address treatment resistance.
The study's findings on EMPD survival rates and the progress in breast cancer treatment highlight the importance of continued research and personalized approaches in oncology.
The research also adds to the understanding of how certain cells, such as CHL1 fibroblasts, can support cancer growth and evade immune attack, as shown in studies by Columbia University researchers.
What this adds
The study does not specify the exact mechanisms behind the survival differences between men and women with EMPD.
The research on CHL1 fibroblasts provides new insights into how lung cancers can evade immune attacks, potentially leading to new treatment strategies.
What's confirmed
- A study published in Medscape revealed that women with extramammary Paget disease (EMPD) exhibit a lower risk of cancer-specific and all-cause mortality compared to men, based on data from the Surveillance, Epidemiology, and End Results (SEER) program from 2004 to 2021.
- The research was supported in part by the Biostatistics Shared Resource of the Winship Cancer Institute at Emory University, which is funded by the National Institutes of Health/National Cancer Institute.
- This finding adds to the growing body of evidence suggesting that gender may play a significant role in the survival rates of certain cancers.
- The study highlights the importance of considering gender differences in cancer outcomes and treatment strategies.
- While the study provides valuable insights, it does not establish the underlying mechanisms responsible for the observed survival differences between men and women with EMPD.
- Further research is needed to explore the biological and environmental factors that contribute to these disparities.
- Additionally, the combination of Inluriyo and another therapy doubled the median progression-free survival in the phase 3 EMBER-3 trial, compared to Inluriyo alone, with a PFS of 11 months versus five and a half months.
- Dr. Komal Jhaveri of Memorial Sloan Kettering Cancer Center, the principal investigator for the EMBER-3 and EMBER-4 trials, emphasized the urgent need for effective and safe treatment options for patients with disease progression on adjuvant or first-line therapy.
- The EMBER-4 study, involving 8,000 patients, is assessing Inluriyo's potential in reducing recurrence in early-stage breast cancer after standard of care endocrine therapy.
- These advancements in cancer treatment underscore the ongoing efforts to improve patient outcomes and address treatment resistance.
- The study's findings on EMPD survival rates and the progress in breast cancer treatment highlight the importance of continued research and personalized approaches in oncology.
- The research also adds to the understanding of how certain cells, such as CHL1 fibroblasts, can support cancer growth and evade immune attack, as shown in studies by Columbia University researchers.
What's still developing
- Tucatinib Maintenance Extends PFS Across HER2+ Breast Cancer Subgroups De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival FDA Approves Palbociclib Plus Anti-HER2 and Endocrine Therapy as Maintenance in Breast Cancer Tucatinib Maintenance Improves PFS Across Key Subgroups in HER2+ MBC Aditya Bardia, MD, MPH, FASCO; Benjamin Scheier, MD Aditya Bardia, MD, MPH, FASCO; Priya Kumar, MBBS, MS Aditya Bardia, MD, MPH, FASCO; Mohammad F.
- The DAISY trial shows that HER2DX and DNADX genomic assays can predict T-DXd response in metastatic breast cancer by measuring HER2 levels and DNA instability.
- FDA grants priority review to T-DXd for high-risk HER2-positive early breast cancer with residual disease, after trial shows markedly better recurrence-free survival than T-DM1.
- The 10th Dermatology Drug Development Summit returns in 2026 as the leading premier forum dedicated to advancing the discovery, development, and commercialization of innovative therapies for inflam The 10th Antifibrotic Drug Development Summit is the industry's only dedicated forum focused on cross-indication antifibrotic drug development Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.
- The combination is approved for the same cohort as the monotherapy: ER-positive, HER2-negative breast cancer patients with ESR1 mutations whose disease progressed after at least one line of endocrine therapy.
- “We found lots of cancer genes but also genes associated with long-term changes in liver metabolism,” said Foad Rouhani, one of the authors of the paper and a professor at King’s College in London.
- Liver cells showed many more mutations than blood cells, even though chemotherapy is a systemic treatment.
- “If we understand the mechanism, can we then eventually be able to design next-generation chemotherapies which are highly effective at treating the cancer but actually leave the background tissue largely untouched?” said Rouhani.
- Platinum-based chemotherapy — in particular cisplatin and carboplatin — are a lifeline for children with certain cancers.
- These treatments, for instance, transformed the prognosis of hepatoblastoma, a rare cancer of the liver that is the most commonly diagnosed in childhood, from a five-year survival rate of 20% to more than 80% for localized tumors.
- However, these medications work by damaging the DNA of cancer cells, and they are also known to cause mutations in the DNA of healthy cells, potentially raising the risk of new cancers later in life.
- They include treatments for different forms of cancer, haemophilia A, generalised myasthenia gravis and short bowel syndrome, as well as a rabies vaccine.